Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with graves' disease

Journal of Nuclear Medicine

Volumn 44, Issue 10, 2003, Pages 1547-1555

  Burggasser, Georg ^a   Hurtl, Ingrid ^b   Hauff, Wolfgang ^a   Lukas, Julius ^a   Greifeneder, Michaela ^b   Heydari, Bamdad ^b   Thaler, Arnulf ^a   Wedrich, Andreas ^a   Virgolini, Irene ^b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b City of Vienna Hospital Lainz   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

99mTc CeoSpect; 99mTc NeoTect; 99mTc P829; Graves' disease; Somatostatin receptor; Somatostatin receptor imaging; Thyroid associated orbitopathy

Indexed keywords

DEPREOTIDE TC 99M; SOMATOSTATIN RECEPTOR; TRACER; CYCLOPEPTIDE; DIAGNOSTIC AGENT; P 829; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG UPTAKE; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; GRAVES DISEASE; HUMAN; LUNG CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MYOFIBROSIS; PRIORITY JOURNAL; SCINTIGRAPHY; SYMPTOM; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORNEA; EXTRAOCULAR MUSCLE; FEMALE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; ORBIT; PREDICTION AND FORECASTING; SCINTISCANNING; STATISTICS; TISSUE DISTRIBUTION; VALIDATION STUDY;

CORNEA; FEMALE; GRAVES DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCULOMOTOR MUSCLES; ORBIT; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; STATISTICS; TISSUE DISTRIBUTION;

EID: 0642310797     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Reubi JC, Maurer K, vonWerder K, Torhorst J, Klijn GM, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987;47:551-558.
2. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors Cancer Res. 1994;54:690-700.
3. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA. 1992;89:251-255.
4. Yamada Y, Reisine S, Law SF, et al Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992;6:2136-2142.
5. Yamada Y, Kagimoto S, Kubota A, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human sontatostatin receptor subtype. Biochem Biophys Res Commun. 1993;195:844-852
6. Yasuda K, Res-Domiano S, Breder CA, et al. Cloning of a novel somatostatin receptor, SST3, coupled to adenylate cyclase. J Biol Chem. 1992;267:20422-20428.
7. Demchyschyn LL, Srikant CB, Sunahara RK, et al Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20 Mol Pharmacol 1993;43:894-901.
8. Bell GI, Yasada K, Kong H. Molecular biology of somatostatin receptors Ciba Found Symp. 1995;190:65-88.
9. Corness JD, Demchyschyn LL, Seeman P A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides FEBS Lett. 1993;321:279-284
10. Rohrer L, Raulf F, Bruns C, Buetter R, Hofstaedter F, Schule R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA. 1993;90:4196-4200
11. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer. Eur J Clin Invest. 1997;27:645-647.
12. Virgolini I, Traub T, Leimer M, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-58.
13. Virgolini I, Traub T, Novotny C, et al. New trends in peptide receptor radioligands. Q J Nucl Med. 2001;45:153-159.
14. Virgolini I. Experience with indium and yttrium labeled somatostatin analogs. Curr Pharm Design. 2002;8:1781-1807.
15. 3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
16. 111In-DTPA-D-PHe-1-OCT. Eur J Nucl Med. 1996;23:1388-1399
17. Maina T, Stolz B, Albert R, Bruns C, Koch P, Maecke H. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labeled with technetium-99m. Eur J Nucl Med. 1994;21:437-444.
18. 99mTc-complex. Liebigs-Annalen. 1996;1463-1469.
19. Bangard M, Behe M, Bender H, et al. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med. 1998;25:837.
20. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016-1022
21. 99m-P829. Cancer Res. 1998;58:1850-1859.
22. Blum J, Handmaker H, Rinne N. The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1998;115:224-232
23. 1-octreotide in patients with neuroendocrine tumors J Nucl Med. 2000;41:1514-1518.
24. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subjects of somatostatin receptors on cultured human lymphocytes. J Biol Chem. 1989;264:949-952.
25. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumors. Virchows Arch. 2001;439:787-797.
26. Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer. 1999;85:189-198.
27. Raderer M, Valencak J, Pfeffel F, et al. Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type J Natl Cancer Inst. 1999;91:716-718.
28. Tsutsumi A, Takano H, Ichikawa K, Kobayashi S, Koike T. Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells. Cell Immunol 1997;181:44-49.
29. Weetman AP. Graves' disease. N Engl J Med. 2000;343:1236-1248
30. Wiersinga WM, Gerding MN, Prummel MF, Krenning EP. Octreotide scintigraphy in thyroidal and orbital Graves' disease. Thyroid 1998;8:433-436.
31. Gerding MN, Van der Zant FM, Van Royen EA, et al. Octreotide-scintigraphy is a disease activity parameter in Graves' ophthalmopathy. Clin Endocrinol. 1999;50:373-379.
32. Gorman CA. Clever is not enough: NOSPECS is form in search of function. Thyroid. 1991;1:353-355
33. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, vander Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach Br J Ophthalmol. 1989;73:639-644.
34. Kahaly G, Diaz M, Just M, Beyer J, Lieb W Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy Thyroid. 1995;5:107-111.
35. Prummel MF, Suttrop-Schulten MS, Wiersinga WM, Verbeek AM, Mourtis MP, Koornneef L A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy. Ophthalmology. 1993;100:556-561
36. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78.
37. Leech NJ, Dayan CM. Controversies in the management of Graves' disease. Clin Endocrinol. 1998;49:273-280.
38. Hiromatsu Y, Kojima K, Ishisaka N, et al Role of magnetic resonance imaging in thyroid-associated ophthalmopathy, its predictive value for therapeutic outcome of immunosuppressive therapy Thyroid. 1992;2:299-305.
39. Olivari N. Thyroid-associated orbitopathy: transpalpebral decompression by removal of intraorbital fat - experience with 1362 orbits in 696 patients over 13 years Exp Clin Endocrinol Diab. 1999;107:208-211.
40. Ossoinig KC. Diagnosis und Management of Graves' Orbitopathy with Standardized Echography. Iowa City, IA, KC Ossoinig; 2000:1-13.
41. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol. 2000;25:63-71.